A Suggested Approach to Simplify and Improve Cervical Screening in the United States

Journal of Lower Genital Tract Disease

Volumn 20, Issue 1, 2016, Pages 1-7

  Schiffman, Mark ^a   Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CLINICAL PRACTICE; COLPOSCOPY; FEMALE; GOAL ATTAINMENT; HISTOPATHOLOGY; HUMAN; MEDICAL HISTORY; PRACTICE GUIDELINE; PUBLIC HEALTH; REVIEW; RISK MANAGEMENT; SERODIAGNOSIS; SOCIAL ACCEPTANCE; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; EARLY CANCER DIAGNOSIS; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PROCEDURES; UTERINE CERVICAL NEOPLASMS;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRIDAE; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84951850338     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0000000000000170     Document Type: Review

References (63)

1. Kinney W, Wright TC, Dinkelspiel HE, Increased cervical cancer risk associated with screening at longer intervals. Obstet Gynecol 2015; 125: 311-5.
2. Blatt AJ, Kennedy R, Luff RD, Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol 2015; 123: 282-8.
3. Giorgi-Rossi P, Arbyn M, Meijer CJ,. Cervical cancer screening by human papillomavirus testing followed by cytology triage. JAMA Intern Med 2015; 175: 1068.
4. Schiffman M, Wentzensen N, Wacholder S, Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011; 103: 368-83.
5. Katki HA, Kinney WK, Fetterman B, Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011; 12: 663-72.
6. Zhao FH, Hu SY, Zhang Q, Risk assessment to guide cervical screening strategies in a large chinese population. Cancer Epidemiol Biomarkers Prev. In press.
7. Saslow D, Solomon D, Lawson HW, American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Lower Gen Tract Dis 2012; 16: 175-204.
8. Massad LS, Einstein MH, Huh WK, 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Lower Gen Tract Dis 2013; 17 (5 Suppl 1): S1-S27.
9. Rijkaart DC, Berkhof J, van Kemenade FJ, Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012; 130: 602-10.
10. Huh WK, Ault KA, Chelmow D, Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Lower Gen Tract Dis 2015; 19: 91-6.
11. Naucler P, Ryd W, Tornberg S, Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101: 88-99.
12. Bergeron C, Ronco G, Reuschenbach M, The clinical impact of using p16 immunochemistry in cervical histopathology and cytology: An update of recent developments. Int J Cancer 2015; 136: 2741-51.
13. Zhao C, Moriarty AT, Ghofrani M, Human papillomavirus testing and reporting rates in 2012: results of a College of American Pathologists national survey. Arch Pathol Lab Med 2015; 139: 757-61.
14. Wentzensen N, Fetterman B, Castle PE, p16/Ki-67 dual stain cytology for detection of cervical precancer in hpv-positive women. J Natl Cancer Inst 2015; 107.
15. Cox JT, Castle PE, Behrens CM, Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013; 208: 184 e1-e11.
16. Wentzensen N, Sun C, Ghosh A, Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012; 104: 1738-49.
17. Bierkens M, Hesselink AT, Meijer CJ, CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer 2013; 133: 1293-9.
18. Louvanto K, Franco EL, Ramanakumar AV, Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. Int J Cancer 2015; 136: E638-45.
19. Hildesheim A, Hadjimichael O, Schwartz PE, Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 1999; 180 (3 Pt 1): 571-7.
20. Gage JC, Schiffman M, Katki HA, Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 2014; 106.
21. Marcus PM, Prorok PC, Miller AB, Conceptualizing overdiagnosis in cancer screening. J Natl Cancer Inst 2015; 107.
22. Schiffman M, Castle PE, Jeronimo J, Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
23. Bouvard V, Baan R, Straif K, A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10: 321-2.
24. Kjaer S, Hogdall E, Frederiksen K, The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006; 66: 10630-6.
25. Chen HC, Schiffman M, Lin CY, Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011; 103: 1387-96.
26. Schiffman M, Glass AG, Wentzensen N, A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1398-409.
27. Schiffman M, Herrero R, Desalle R, The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84.
28. Plummer M, Schiffman M, Castle PE, A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195: 1582-9.
29. Rodriguez AC, Schiffman M, Herrero R, Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102: 315-24.
30. Kjaer SK, Frederiksen K, Munk C, Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-88.
31. Guan P, Howell-Jones R, Li N, Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 2349-59.
32. Schiffman M, Clifford G, Buonaguro FM,. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8.
33. Schiffman M, Burk RD, Boyle S, A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol 2015; 53: 52-9.
34. Wentzensen N, Schiffman M, Dunn T, Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009; 125: 2151-8.
35. Darragh TM, Colgan TJ, Cox JT, The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Lower Gen Tract Dis 2012; 16: 205-42.
36. Schiffman M, Rodriguez AC,. Heterogeneity in CIN3 diagnosis. Lancet Oncol 2008; 9: 404-6.
37. Wentzensen N, Walker JL, Gold MA, Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol 2015; 33: 83-9.
38. Stoler MH, Schiffman M,. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285: 1500-5.
39. Nayar R, Wilbur D,. The Bethesda System for Reporting Cervical Cytology. Definitions, Criteria, and Explanatory Notes. 3rd ed. Cham, Switzerland: Springer International Publishing; 2015.
40. Kovacic MB, Castle PE, Herrero R, Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006; 66: 10112-9.
41. Zuna RE, Wang SS, Rosenthal DL, Determinants of human papillomavirus-negative, low-grade squamous intraepithelial lesions in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS). Cancer 2005; 105: 253-62.
42. Kinney WK, Manos MM, Hurley LB, Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998; 91: 973-6.
43. Thomsen LT, Frederiksen K, Munk C, High-risk and low-risk human papillomavirus and the absolute risk of cervical intraepithelial neoplasia or cancer. Obstet Gynecol 2014; 123: 57-64.
44. Liaw KL, Hildesheim A, Burk RD, A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183: 8-15.
45. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383-92.
46. Gage JC, Katki HA, Schiffman M, The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. Cancer Cytopathol 2014; 122: 842-50.
47. Katki HA, Schiffman M, Castle PE, Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. J Lower Gen Tract Dis 2013; 17 (5 Suppl 1): S50-5.
48. Ronco G, Dillner J, Elfstrom KM, Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-32.
49. Sankaranarayanan R, Nene BM, Shastri SS, HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
50. Katki HA, Schiffman M, Castle PE, Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Lower Gen Tract Dis 2013; 17 (5 Suppl 1): S36-42.
51. Schiffman M,. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007; 111: 145-53.
52. Franco EL, Cuzick J,. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 26 (Suppl 1): A16-23.
53. Cuzick J, Cadman L, Mesher D, Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013; 108: 908-13.
54. Szarewski A, Ambroisine L, Cadman L, Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-42.
55. Stoler MH, Ronnett BM, Joste NE, The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status. Am J Surg Pathol 2015; 39: 729-36.
56. Katki HA, Schiffman M, Castle PE, Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Lower Gen Tract Dis 2013; 17 (5 Suppl 1): S56-63.
57. Schiffman M, Vaughan LM, Raine-Bennett TR, A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecol Oncol 2015; 138: 573-8.
58. Reid JL, Wright TC Jr, Stoler MH, Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. Am J Clin Pathol 2015; 144: 473-83.
59. Schiffman M, Wentzensen N,. Transitioning to a new era in cervical cancer screening. Gynecol Oncol 2015; 136: 175-7.
60. Katki HA, Schiffman M, Castle PE, Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Lower Gen Tract Dis 2013; 17 (5 Suppl 1): S28-35.
61. Franco EL, Tsu V, Herrero R, Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine 2008; 26 (Suppl 11): L88-95.
62. Rodriguez AC, Solomon D, Herrero R, Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am J Epidemiol 2013; 178: 752-60.
63. Katki HA, Gage JC, Schiffman M, Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. J Lower Gen Tract Dis 2013; 17 (5 Suppl 1): S69-77.